CSPC Pharmaceutical Group (HK:1093) has released an update. CSPC Pharmaceutical Group has scheduled a board meeting for November 15, 2024, to ...

1 Day CHJTF -14.01% DJIA 0.59% S&P 500 0.38% Health Care/Life Sciences 2.54% Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...

The global nanoparticle drug delivery systems market size is estimated to grow by USD 54.90 billion from 2024-2028, according ...

AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases. On Monday, AstraZeneca plc (NASDAQ:AZN) entered into an exclusive ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

DelveInsight's 'Severe Asthma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline severe asthma ...

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical.